Development of Opioid and Adjuvant Fixed Combination Dosage Forms for the Treatment of Chronic Pain with Reduced Addiction Potential (R41/R42)
The purpose of this announcement is to fund meritorious applications from small business organizations that aim to develop of opioid and adjuvant drug combinations within a single dosage form for treatment of a pain condition. The drug combination should provide improved analgesia when compared with the same dose (morphine equivalents) of opioid monotherapy. Such dosage forms should minimize opioid exposure while optimizing analgesia, in order to reduce risk of addiction and limit severity of other opiate adverse effects.
General information about this opportunity
Last Known Status
Active
Program Number
PA-13-388 Federal Agency/Office
Agency: Department of Health and Human ServicesOffice: National Institutes of Health
Type(s) of Assistance Offered
Grant Who is eligible to apply/benefit from this assistance?
Applicant Eligibility
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. What is the process for applying and being award this assistance?
Deadlines
01/07/2017 Other Assistance Considerations
Formula and Matching Requirements
This program does not have cost sharing or matching requirements. Who do I contact about this opportunity?
Headquarters Office
NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
Website Address
http://grants.nih.gov/grants/guide/pa-files/PA-13-388.html
E-mail Address
FBOWebmaster@OD.NIH.GOV
Financial Information
Obligations
$0.00
